Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

50.99USD
6:21pm GMT
Change (% chg)

$-0.37 (-0.72%)
Prev Close
$51.36
Open
$51.35
Day's High
$51.89
Day's Low
$50.96
Volume
1,457,859
Avg. Vol
3,185,250
52-wk High
$68.87
52-wk Low
$44.30

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 30.48 33.70
EPS (TTM): 2.74 -- --
ROI: 18.60 14.95 14.45
ROE: 30.97 16.27 15.96

Bristol-Myers says Starboard nominated five directors, bought shares

Bristol-Myers Squibb Co said on Wednesday that activist hedge fund Starboard Value LP intends to nominate five directors to the U.S. drugmaker's board, one month after it announced a $74 billion deal to acquire peer Celgene Corp.

4:54pm GMT

UPDATE 1-Bristol-Myers says Starboard nominated five directors, bought shares

Feb 20 Bristol-Myers Squibb Co said on Wednesday that activist hedge fund Starboard Value LP intends to nominate five directors to the U.S. drugmaker's board, one month after it announced a $74 billion deal to acquire peer Celgene Corp.

4:45pm GMT

Bristol-Myers says Starboard nominated five directors, bought shares

BOSTON, Feb 20 Bristol-Myers Squibb Co. said on Wednesday that activist hedge fund Starboard Value LP wants to add five directors to its board and bought one million shares after the pharmaceutical company said it plans to buy biotech company Celgene Corp.

3:05pm GMT

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

16 Feb 2019

Merck, Pfizer drug combo extends kidney cancer survival -study

Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

16 Feb 2019

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

16 Feb 2019

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion (57 billion pounds) deal to buy Celgene Corp, people familiar with the matter said on Friday.

16 Feb 2019

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Feb 15 Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

16 Feb 2019

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

15 Feb 2019

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Feb 15 Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

15 Feb 2019

Earnings vs. Estimates